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Abstract 
Background: HIV infection is the greatest risk factor for acquiring TB infection and developing the disease. TB 
enhances HIV replication by accelerating the natural evolution of HIV infection; it is the leading cause of sickness and 
death of people living with HIV.  
Objectives: To estimate the survival of HIV/AIDS co-infected patients and to identify predictors of survival based on 
data obtained from Ambo referral hospital, West Shoa Zone in Oromia Regional State, Ethiopia. 
Methods: This retrospective study was conducted based on data collected in 501 cases of HIV-infected TB patients of 
age 15 years and above who started anti-TB treatment between September 1, 2006 and August 31, 2011 and followed 
until February 29, 2012. The Kaplan-Meier method and the log-rank test were used to compare the survival experience 
of different categories of patients. The Cox regression model was employed to identify predictors of mortality. 
Results: A total of 79 deaths occurred during the follow up period of 78.66 months. Of these 49 patients died within 
the first nine months after initiation of the anti-TB treatment and the remaining 30 died after finishing the treatment; 
the last death occurred at 67.83 months. The overall median survival of the 79 death cases was 27.7 months. The Cox 
regression analysis showed that initial weight, TB site (pulmonary or extra-pulmonary), WHO clinical stage, 
functional status and CD4 count were significant risk factors.  The most important predictors associated with higher 
risk of death at 0.05 level of significance were: low initial weight, low CD4 count, WHO stages III and IV as well as   
ambulatory and bedridden physical conditions. 
Conclusion: A careful monitoring of the health status of patients with low initial weight, low CD4 cell count, 
advanced WHO stages III & IV, ambulatory and bedridden functional status is necessary to improve the survival of 
HIV-TB co-infected patients at initiation of and during anti-TB treatment.  [Ethiop. J. Health Dev.  2013;27(2):88-93] 
 
Introduction 
According to a WHO report of 2009, the people living 
with HIV (PLWHIV) are estimated to have a 20 times 
higher risk of developing TB disease compared to people 
living without HIV infection in countries with an HIV 
prevalence of at least 1%. The global impact of the 
converging dual epidemics of TB and HIV remains as 
one of the major public health problems or challenges of 
our time. WHO reported that 9.27 million of the 
estimated new cases of TB of which occurred in 2007, 
31% were in sub-Saharan Africa and about 1.37 million 
(14.8%) of these being among PLWHIV. About 79% 
HIV-positive TB incident cases, occurred in Africa in 
2007. In the same year, there were 456,000 TB-related 
deaths among HIV-positive patients accounting for 23% 
of the global HIV/AIDS mortality. Southeast Asia was 
the second most affected region with 11% of global new 
TB cases in 2007 (1). 
 
The latest WHO report on global TB control indicated 
that there were an estimated 8.8 million incident cases 
and 1.4 million deaths from TB in 2010, where 1.2 
million (12–14%) of the new TB cases were amongst 
HIV-infected people in 2010, and TB caused the death of 
an estimated 0.35 million HIV-infected people. The 
proportion of HIV-TB-co-infected persons is highest in 
Africa; Africa accounted for overall 82% of TB cases 
among people living with HIV worldwide in 2010 (2). 
 
HIV infection is the most common predictor of TB 
incidence, and the other way round, TB is a common 
opportunistic infection in sub-Saharan Africa. Thus, the 
countries in the sub-region continue taking the leading 
position in HIV/TB morbidity and mortality rate, where 
the TB epidemic was primarily driven by HIV infection. 
Ethiopia is one among these countries most heavily 
affected by HIV and TB co-infection. The World Health 
Organization ranked Ethiopia as seventh  among the 22 
high burden countries with TB where the estimated 
annual incidence and prevalence, respectively, were 379 
and 643 cases per 100,000 populations (3). The 
prevalence of HIV among TB patients was estimated as 
high as 41% (4, 5). The WHO global report 2008 
estimated that in Ethiopia 40% of TB patients tested for 
HIV were found to have been HIV-positive. In Ethiopia 
routine data obtained from 44 locations in the year 
2005/6 showed that about 41% of TB patients were HIV-
positive. In addition, another routine data set collected in 
2006/07 estimated that some 31% of TB patients were 
HIV-positive (6). TB was the cause of 76,000 deaths in 
Ethiopia, out of which 30% were among HIV-positive 
patients (1). In addition to rate of mortality caused by the 
co-infection the extent of the negative impact on the 
 
1Department of Statistics, Wollega University; E-mail: dibaabee@gmail.com; 
2Department of Statistics, College of Natural Sciences, Addis Ababa University; E-mail: 
wenchekoeshetu@yahoo.com. 
Survival of HIV-TB co-infected adult patients under ART in Ambo referral hospital, Ethiopia     89 
 
quality of livelihood resulting from mental disorders was 
studied (7, 8).    
 
Given the above introduction about HIV-TB co-infection, 
its prevalence and rates of mortality in the developing 
world in general and in Ethiopia, in particular, this study 
had the objectives to estimate survival and identify risk 




This was a retrospective study based on 501 cases of 
HIV-infected TB patients of age 15 years and above who 
received anti-TB treatment in Ambo referral hospital, in 
Ambo, Oromia Regional State, Ethiopia between 
September 1, 2006 and August 31, 2011 and followed 
until February 29, 2012.  
 
The Hospital started providing free ART service in 2006. 
It had a separate ART clinic and units for ART follow up 
for PLWHIV. Data about HIV infection were extracted 
from the available medical registers that were designed 
by the Federal Ministry of Health (FMOH) for 
uniformity of use in the country in order to document 
relevant clinical and laboratory variables. The registers 
included the Pre-ART register (register of patients at 
their first visit), the ART register (registration after ART 
initiation), and the follow-up patient form. The hospital 
also has a separate clinic and units for TB treatment and 
follow-up. Data regarding TB treatment and follow-up 
were recorded in standard register forms prescribed by 
FMOH.  For this study, both ART and TB registers were 
thoroughly reviewed to record information about HIV 
infected persons who started ART and had been under 
anti-TB treatment.  
  
The Hospital top management gave approval to access 
the patient register forms upon a request made by Addis 
Ababa University. The data were collected by a data 
clerk from the hospital and a statistician. Patient intake 
and follow up forms were cross examined for 
inconsistencies so that data quality could be ensured. 
After coding and cleaning of the data the analysis was 
done using SPSS, SAS, and STATA software. 
 
The response/outcome variable of this study was survival 
time. In this study the length of survival time an adult 
HIV-TB co-infected patient had lived (measured in 
months) from start of anti-TB treatment until the date of 
death.  The predictor/explanatory variables included in 
the study were: age (in years), sex (male, female), marital 
status (never married, married, other status), body weight 
(in kgs.), level of education (no education/illiterate, 
primary, secondary or above), substance (smoking, 
alcohol) use (no, yes), CD4 cells count (cells/mm3), site 
of TB, WHO clinical stages (stages I, II, III and IV), 
functional status (working, ambulatory, bedridden), and 
type of regimen (D4T-based,  AZT-based). A person (a 
patient in this case) who is able to perform usual work in 
and out of the house, perform normal activities, play or 
go to school (for children) is considered as working. On 
the other hand a patient who is capable of performing 
activities for daily living is considered as ambulatory 
while one who is unable to perform such activities is 
bedridden (6). Combinations of drugs that contain the 
regimen AZT and D4T in the treatment of TB co-
infection are labeled as AZT-based and D4T-based, 
respectively.       
 
Tuberculosis site means locality of the disease in the 
human body. It is a known fact that TB can affect 
virtually any tissue or organ but most commonly it 
affects the lungs; it also occurs in other sites most 
commonly pleura, lymph nodes, spine, joints, genito- 
urinary tract, the nervous system or abdomen, and it 
represents 14% of all TB cases in the world and 12% of 
all TB in high burden countries. TB infection is broadly 
classified into pulmonary tuberculosis (PTB) (accounting 
for 85% of all tuberculosis cases) and, extra-pulmonary 
tuberculosis (EPTB) (comprising 15% of all tuberculosis 
cases). Pulmonary tuberculosis is further classified into 
smear-positive PTB accounting for 75-80% of all PTB 
and smear-negative PTB that accounts for about 20-25% 
of all PTB cases worldwide (6). For the data used in this 
study it was not possible to distinguish between smear-
positive and smear-negative PTB cases Hence, on 
account of the background provided above, it is believed 
that most of PTB cases were likely to be smear-positive. 
 
Results  
Among the study subjects 248 were females and 253 
were males; 291 were married, 97 were never married, 
and the marital status of 113 was not established;114 
were illiterate, 216 had primary level of education, 141 
completed at least high school education;  while 306 had 
no habit of substance use the remaining 195 were 
exposed to substance use; 181 and 320, respectively, had 
EPTB and PTB; 120, 44 and 337 had ambulatory, 
bedridden and working functional status; WHO clinical 
stages III and IV prevailed in 307 and 95 cases, 
respectively, while 99 cases were in WHO stages I and 
II. There were 215 and 286 subjects, respectively, to 
whom regimen types AZT and D4T were prescribed 
(Table 1). 
 
The overall median age, weight and CD4 cell count of 
the HIV-TB co-infected patients after initiation of anti-
TB treatment were: 31 years (inter-quartile range 27-38 
years), 48 kgs. (inter-quartile range 42.5-54 kgs.) and 137 
cells/mm3 (inter-quartile range 65-226 cells/mm3) with 
median survival time 27.7 months (inter-quartile range 
9.56-44.60 months). For the deceased patients the median 
age, weight and CD4 cell count after initiation of anti-TB 
treatment were: 30 years (inter-quartile range 26-35 
years), 42 kgs (inter-quartile range 30.5-49 kgs) and 69 
cells/mm3 (inter-quartile range 40-106 cells/mm3) with 
median survival time 7 months (inter-quartile range 4.86-
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Table 1:  Distribution of the categorical  socio-demographic and health predictors/variables of HIV-TB co-
infected patients taking anti-TB treatment in Ambo referral  hospital, Ambo, Ethiopia, 2012 ( =501). 
Demographic and health Predictors/variables                           Status of censoring or event 
Total Death Censored Death (%) 
Sex Female  248 41 207 16.5 
Male 253 38 215 15.0 
Marital status 
 
Never Married 97 20 77 20.6 
Married 291 39 252 13.4 
Others 113 20 93 17.7 
Level of education No Education 144 21 123 14.6 
Primary 216 35 181 16.2 
Secondary or above 141 23 118 16.3 
Substance use (tobacco, 
alcohol) 
No  306 46 260 15.0 
Yes 195 33 162 16.9 
TB site EPTB 181 17 164 9.4 
PTB 320 62 258 19.4 
Functional status Ambulatory 120 27 93 22.5 
Bedridden 44 19 25 43.2 
Working 337 33 304 9.8 
WHO clinical stage Stage I or II 99 5 94 5.1 
Stage III 307 49 258 16.0 
Stage IV 95 25 70 26.3 
Regimen type AZT-based 215 30 185 14.0 
D4T-based 286 49 237 17.1 
 
 
Table 2: Summary statistics related to the continuous variables included in the study of HIV-TB  





Min. Max Median 
  
Censored Survival time 1 78.66 31.89 15.37 46.51 
Age 17 78 31 27 38 
Weight 15 78 49 44 55 
CD4 count 6 699 159 80 244.75 
Death Survival time  9.20 67.83 7.03 4.86 14.56 
Age 19 57 30 26 35 
Weight 16 64 42 30.5 49 
CD4 count 2 514 69 40 106 
Overall Survival time 0.9 78.66 27.7 9.56 44.6 
Age 17 78 31 27 38 
Weight 15 78 48 42.5 54 
CD4 count 2 699 137 65 226 
 
From the total of 501 patients included in this study 79 
subjects (15.8%) died during the follow-up time. Of these 
49 patients died within the first nine months after 
initiation of the anti-TB treatment; the remaining 30 died 
after finishing the treatment. The minimum and 
maximum survival lengths among the latter group were 
9.2 months and 67.8 months, respectively. 
 
A log-rank test was performed to check for existence of 
any significant differences in survival experience 
between/among various levels of the categorical 
variables included in the study. The results showed no 
significant differences in survival experiences 
between/among the categories of sex, marital status, 
education, substance use, and regimen and, therefore, 
they were statistically non-significant for consideration 
in the subsequent analysis. On the other hand, differences 
in survival were observed among the categories of TB 
site, functional status and WHO clinical stage. These and 
the remaining two continuous variables namely, weight 
and CD4 cell count were included for consideration in 
the Cox multiple regression model. We note, however, 
that in the result provided below a comparison about 
survival differential will be made between the baseline 
CD4 count and a higher category where a 50 cells/mm3 
increase of  CD4 count  for ease of understanding the 
risk.  
 
The bivariate regression analysis with single 
factors/predictors indicated that not all were  important to 
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be included in the multivariable analysis stage on the 
basis of the selection/elimination with the lax criterion of 
0.25 level of significance. This selection process gave 
rise to a Cox regression model that included only five 
covariates namely, weight, TB site, functional status, 
WHO clinical stage and CD4 count; these were found 
significant at 0.05 level. Further checks for confounding 
and interactions showed that there were no confounders 
and interaction terms. The regression model with the 
above covariates was accepted as a provisional model. 
After further checking for the validity of the 
provisionally accepted model the model containing  the 
five main effects covariates was accepted as the final 
model (Table 3).  
 
Table 3:  Results of the multiple Cox regression analysis about HIV-TB co-infected patients  
taking anti-TB treatment in Ambo referral hospital, Ambo, Ethiopia, 2012, (n=501) 
Factors/variables Sig. Estimated Hazard 
Ratio 
95% CI for Hazard Ratio 
Lower Upper 
Weight <0.0001 0.915 0.891 0.939 
TB site – PTB 0.0033 2.330 1.326 4.096 
Ref. group (EPTB)     
Functional Status 0.0080    
Ambulatory 0.0098 2.057 1.190 3.555 
Bedridden 0.0062 2.423 1.285 4.568 
Ref. Group (working)     
WHO 0.0105    
WHO III 0.0250 2.918 1.144 7.442 
WHO IV 0.0032 4.416 1.647 11.839 
Ref. group (WHOI/II)     
CD4 <0.0001 0.992 0.988 0.995 
 
In the remaining part of this section interpretations of the 
results are given using estimated hazard ratios and their 
respective estimated 95% confidence intervals. 
 
Weight: The estimated hazard ratio for weight,  
0.915 [95% CI: 0.891-0.939, p<0.0001]. Suppose we 
took an increment of weight by five kgs to make 
comparisons. Then, the estimated hazard ratio for a five 
kgs increase in initial weight is 0.64 =exp (-0.08927×5). 
This means that the risk of death of a patient whose 
weight was 5kgs higher than another patient in the 
immediate lower weight category was 36% lower 
controlling for other covariates.  
 
CD4 cell count: For CD4 cell count the estimated hazard 
ratio,  0.992 [95% CI: 0.988-0.995, p<0.0001]. For 
appropriateness of interpretation we took the estimated 
hazard ratio for a 50 cells/mm3 increase in the baseline 
CD4 cell count which is 0.657=exp (-0.00838×50). This 
means that patients whose CD4 cell count was higher by 
50cells/mm3 died at hazard rate lower by 34.3% relative 
to the next immediate lower category of CD4 cell count 
group controlling for other variables in the model.  
 
TB site: The estimated hazard ratio of PTB compared to 
EPTB was  = 2.33 [95% CI: 1.326 - 4.096, p=0.0033] 
revealing that the rate of dying among patients with PTB 
was 2.33 times higher than among EPTB patients 
controlling for other variables in the model.  
 
Functional status: Patients with ambulatory and 
bedridden functional status had =2.057 [95% CI: 
1.190-3.555, p=0.0098] and  = 2.423 [95% CI: 1.285-
4.568, p=0.0062], respectively. These results showed that 
the risk of death in ambulatory and bedridden patients 
were, respectively, 2 times and 2.4 times higher than for  
patients with working functional status. Patients with 
bedridden status for comparison to ambulatory had 
1.18 = exp (0.885-0.721) indicating that bedridden 
patients were 18% more likely to die than those with 
ambulatory functional status controlling for other 
variables in the model. 
 
WHO stages: For patients in WHO stages III and IV the 
respective  2.918 [95% CI: 1.144-7.442, p=0.025] 
and 4.416 [95% CI: 1.647-11.839, p=0.0032] in 
comparison to that of stages I/II controlling for other 
variables in the model. This indicated that the hazards of 
death were, respectively, almost 3 times higher in stage 
III and 4.4 times higher in stage IV compared with the 
risk in stages I/II (both of which were similar).  On the 
other hand, the estimated hazard ratio of stage IV 
compared to stage III is 1.51 = exp (1.48525-1.07090) 
suggesting that patients in stage IV were about 50% more 
likely to die than patients in stage III controlling for other 
variables in the model.   
 
Discussion  
The current study found that initial weight, baseline CD4, 
TB site, functional status and WHO clinical stage were 
significant predictors of survival of HIV-TB co-infected 
patients under anti-TB treatment. In the following part 
we discuss findings obtained in similar research 
undertakings to find out if those findings corroborate or 
discord our results.    
 
The impact of CD4 cell count on survival rate had been 
assessed by several studies the findings of which showed 
that the depletion of CD4 cell count was associated with 
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high risk of death. A retrospective cohort study (9) 
conducted in Ouagadougou, Burkina-Faso showed that 
CD4+ T-cell count < 50 cells/mm3 at HAART initiation 
was   associated with a two-fold higher risk of TB. A 
study conducted in southwest Ethiopia indicated that a 
CD4 lymphocyte count less than 200 cells/mm3 was 
associated with the development of active TB in people 
living with HIV/AIDS (10).  A study conducted in South 
Africa suggested that CD4+ T-lymphocyte count ≤200 
cells/mm3 was associated with progression of AIDS (11). 
A study conducted in Barcelona, Spain (12) revealed that 
survival was worst among patients with <200/mm3 CD4 
cells (  =  1.8, 95% CI 1.2-2.7) (12). A study 
conducted in Brazil indicated that CD4 count <200/mm3 
was a significant risk factor of death of HIV-TB co-
infected patients (13). The finding of the current study 
was in agreement with the findings cited above. 
 
A retrospective study conducted in Hawassa University 
referral hospital, Ethiopia, showed that bedridden 
functional status was one of the major risk factors that 
shortened the longevity among PLWHIV co-infected 
with TB (14). The current study indicated that being 
ambulatory and bedridden functional status significantly 
affected the survival of HIV-TB co-infected patients. 
  
According to the WHO (9), clinical stages III and IV had 
significant impact on survival by increasing the incidence 
of TB among PLWHIV. Advanced WHO clinical stages  
accelerated mortality among TB patients living with HIV 
(10). The findings in (15) indicated that WHO clinical 
stage was identified as a risk factor of HIV-TB co-
infection. The current study also showed that advanced 
WHO clinical stages III and IV were risk factors of 
mortality among HIV-TB co-infected patients.  
 
Initial weight was reported as a risk factor of TB 
activation among PLWHIV (10). A study conducted in 
South Africa suggested that initial weight predicted 
mortality of HIV -TB co-infection (16). The current 
study also identified initial weight as a risk factor. 
  
Several studies suggested that the occurrence of PTB was 
more frequent than EPTB among PLWHIV. Among HIV 
co-infected patients PTB was more serious than EPTB as 
a cause of death (15). A study conducted in Dar-es-
Salaam, Tanzania, showed that, out of a total of 300 TB 
patients tested for HIV, in which 175 (58.3%) were HIV-
infected 104 of the TB patients that were admitted died. 
About two-thirds of the patients, who died had PTB in 
which a significantly higher proportion of deaths 
occurred  among HIV-infected TB patients (29.1% 
versus 15.2%) than among HIV-negative TB patients 
(p=0.005) (17). The findings of (18) based on a study in 
Manipur, India suggested that the site of TB was a risk 
factor of vulnerability of the HIV infected persons to TB. 
An ecological study made in Oromia regional state, 
Ethiopia showed associations between prevalence of HIV 
infection and the incidence of smear-positive 
tuberculosis, smear-negative tuberculosis and EPTB (19). 
The current study also identified PTB significantly 
affected the survival of HIV-TB co-infected patients. 
 
Conclusion and Recommendations 
This study provided some information about risk factors 
that impact the survival of HIV patients during TB 
treatment. It also identified the extent of risk of death 
caused by those factors during and after ant-TB 
treatment.  
 
In this retrospective study the survival status and 
determinants of mortality of 501 HIV-TB co-infected 
patients who received anti-TB treatment at Ambo referral 
hospital was investigated. The patients received the 
treatment from September 1, 2006 to August 31, 2011, 
and were followed up until February 29, 2012. The 
minimum follow-up time was 0.9 month and the 
maximum was 78.66 months. The mortality rate was very 
high in the earlier months of the treatment period and 
stabilized in later stages. Initial weight, TB site, 
functional status, WHO clinical stage and baseline CD4 
cell affected the survival of the patients significantly at 
0.05 levels. Low initial weight, PTB, ambulatory and 
bedridden functional status, advanced WHO clinical 
stages (III and IV) and low baseline CD4 cell count were 
found to be highly associated with high rates of 
mortality. 
 
The findings of the current study suggest that HIV-
positive patients should be told about their health status 
after positive TB diagnoses in order to make them aware 
of the risk of not taking anti-TB treatment. For such 
patients medications and treatment must be affordable 
and easy to access. To that effect all concerned bodies in 
the country, especially FMOH and allied organizations, 
are expected to avail resources.   
 
A limitation of the current study is the subtle assumption 
that all deaths were caused by HIV/TB co-infection. 
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